Allergan buys Aczone Gel 5 percent from QLT USA

Irvine, Calif.

- Allergan has announced it has entered an agreement with QLT USA to purchase Aczone (dapsone) Gel 5 percent, according to socalTech.com.

Allergan will pay about $150 million for all assets related to Aczone, a topical treatment for acne vulgaris, which could reach revenues in excess of $75 million per year.